• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Fosamprenaivr - Key patent, SPC, and data exclusivity expiry (7 country coverage) Product Image

Fosamprenaivr - Key patent, SPC, and data exclusivity expiry (7 country coverage)

  • ID: 2188877
  • October 2014
  • Genericsweb Pty Ltd – Ark Patent Intelligence

Pipeline Selector helps you avoid hours of painstaking reserach by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 7 countries (44 country coverage also available), regulatory issues and key players.

This Pipeline Selector report covers Fosamprenaivr
Fosamprenaivr indications: Treatment of HIV infection optionally in combination with other antiretroviral agents, preferably Ritonavir
Fosamprenaivr innovator: ViiV Healthcare (Lexiva, Telzir); Glaxosmithkline (Lexiva); Vertex (Lexiva)

---

Examples of information found in this online report include:
- Includes key patent publications for 7 countries (see list below)
- Contains SPC protection for every EU state plus patent term extensions in other countries
- Data exclusivity calculated on a country by country basis
- Summary of dosage forms, strengths, indications and active ingredient forms of the brand product
- DMF & Paragraph IV filings
- Litigation alerts
- Marketing authorisation holders in selected territories
- Patent risk analysis via graphical display of data from patent filings
- Hyper-linking READ MORE >

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos